---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-145405"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T22:54:46.464687+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics raises $15M via registered direct offering of 3.2M shares at $4.67

## Summary
- Gross proceeds ~$15M from sale of 3,221,395 shares at $4.67/share; closing expected June 25, 2025.
- Purchasers include existing healthcare-focused institutional investors, executive officers, and directors.
- Net proceeds to support pre-commercialization and launch readiness for CAN-2409 in prostate cancer; BLA submission planned Q4 2026.
- Insider participation signals confidence in Candel's strategy and pipeline.

## SEC filing metadata
- accession: 0001193125-25-145405
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000119312525145405/0001193125-25-145405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000119312525145405/d34398d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-145405
- JSON: https://secwatch.observer/filing/0001193125-25-145405.json
- Plain text: https://secwatch.observer/filing/0001193125-25-145405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.